Ferric citrate: a novel phosphate-binding agent

Abstract

Ferric citrate (KRX-0502; Keryx Biopharmaceuticals, Inc., NY, USA) is a novel phosphate-binding agent presently in Phase III clinical development. Ferric citrate dissociates in the bowel lumen releasing the ferric ion to precipitate with dietary phosphorus, which is then excreted in the stool. Studies to date have shown the agent to be efficacious and safe with only mild gastrointestinal side effects. Absorption of either component of the agent (ferric iron or citrate) has the potential to be of benefit for patients with end-stage renal disease. An ongoing Phase III trial is confirming the safety and efficacy of ferric citrate as a phosphate binder in dialysis patients.

Keywords::

• CKD-MBD
• ESRD
• iron metabolism
• metabolic acidosis
• phosphate binder

Financial & competing interests disclosure

K Umanath, J Lewis and J Dwyer have received research support from Keryx Biopharmaceuticals, Inc. R Niecestro is a Consultant to Keryx. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.